(Reuters) - Germany has joined France in suspending the use of Takeda Pharmaceutical's Actos diabetes drug, due to worries about a possible link to cancer. The move is a blow for the Japanese firm, whose best-selling drug has worldwide sales of close to $5 billion, though the financial impact will be limited by the fact the drug faces looming generic competition in key markets.
